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Objective: Few studies have evaluated health-related quality of life (HRQoL) of patients with chronic hepatitis B (CHB)
in mainland China. We aimed at characterizing the impact of CHB on HRQoL in mainland Chinese and finding out
factors associated with HRQoL.
Methods: 460 CHB patients (323 with CHB only, 54 with compensated cirrhosis and 83 with decompensated cirrhosis)
and 460 pair-matched healthy controls were recruited in Xi’an city. They answered a structured questionnaire including
the Short Form 36 version 2 (SF-36v2), the Chronic Liver Disease Questionnaire (CLDQ) (only for patients), and questions
on socio-demographic and clinical characteristics. A blood sample was collected from each of patients for liver function
tests. SF-36v2 scores were compared between patients and controls overall and by groups by paired-samples t-test,
and CLDQ scores and paired differences of SF-36v2 scores were compared among three patient groups by one-way
ANOVA or Kruskal-Wallis test. Multi-variable linear regression analyses were performed to identify determinants of
HRQoL in patients.
Results: Patients, overall and by groups had significantly lower SF-36v2 scores than controls on all summaries and
domains, with differences higher than the suggested minimally important difference values. Both the SF-36v2 and the
CLDQ showed that HRQoL of patients with cirrhosis further deteriorated, but compensated and decompensated
cirrhosis patients had similar total HRQoL impairments. The gradually increasing impairment with disease progression
was confirmed only on physical components. Impaired liver function and currently taken anti-viral treatment were
associated with lower HRQoL. Education attainment and annual per capita household income had a positive effect on
HRQoL.
Conclusions: Mainland Chinese CHB patients suffered significant HRQoL impairment on all health dimensions, and the
impairment reached a high level on mental health at initial stage of illness and increased gradually on physical health
with disease progression. Attention should be paid to the reduction of patients’ treatment cost burden and the
provision of early health education accompanied with proper treatments.
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Chronic hepatitis B (CHB), caused by persistent infection
with hepatitis B virus (HBV), is a common chronic liver
disease in mainland China. The latest nationwide serosur-
vey showed that 7.2% of the population aged 1–59 years
were positive for HBV surface antigen [1]. Estimated
current HBV carriers run up to 93 million, including 20–
30 million patients with CHB [2], which accounts for
almost one third of the global total [3]. CHB patients
have to cope with many recurrent symptoms in their
long disease histories and are at high risk to develop
fatal complications of cirrhosis and hepatocellular carcin-
oma [4]. Thus, CHB may result in a heavy disease burden
not only in premature death but in health impairment.
As a multidimensional construct describing individ-
uals’ perceptions of their physical, psychological and so-
cial functioning, health-related quality of life (HRQoL)
can holistically assess health outcomes than clinical pa-
rameters, particularly important in chronic diseases, to
help healthcare workers to understand patients’ needs
and provide quality health services [5,6]. With growing
interest in HRQoL in recent years, there have been some
studies focusing on HRQoL of CHB patients [7-11]. A
study from Singapore indicated that HRQoL was similar
in asymptomatic HBV carriers and normal controls, but
obviously decreased in CHB patients and further deteri-
orated with disease progression [7]. Another from Hong
Kong of China found that all individuals with chronic
HBV infection had significantly lower HRQoL than gen-
eral population even among those without any biochem-
ical and clinical abnormalities [8]. Impaired HRQoL in
CHB patients with or without cirrhosis was also re-
ported from several other countries [9-11]. However, few
studies have come from mainland China. The impact of
disease on HRQoL may vary from population to popula-
tion because of differences in socioeconomic status, cul-
tural heritage, religion and life style [12], just like the
differences presented among the previous studies in the
impaired dimensions and degrees and the factors associ-
ated with the impairment [7-11].
HRQoL measured by a generic instrument with gen-
eral public’s preference scores can be easily converted to
a preference index for use in cost-effectiveness evalu-
ation of healthcare interventions [13]. Up to now, only
one study touched upon mainland Chinese preferences
for CHB-related health states [12], in which the standard
gamble method was used and 100 CHB patients and 100
uninfected individuals were enrolled. Country or region-
specific preference estimates may benefit local economic
evaluations.
The objective of this study was to characterize the im-
pact of CHB on HRQoL in mainland Chinese and to
find out factors associated with the impairment of
HRQoL. In addition, we would like to obtain preferenceestimates of different stages of CHB for use in relevant
economic evaluation studies.
Methods
Subjects and data collection
A cross-sectional survey was conducted from April to
July 2010 in Xi’an city, located in the central-northwest
of mainland China with 8.5 million resident population
(over 98% are Han Chinese). Its per capita gross domes-
tic product and HBV prevalence are around the national
average levels.
CHB patients were selected from outpatients from April
to June 2010 and discharged patients from November
2008 to March 2010 of the Eighth Hospital of Xi’an based
on their primary diagnoses of CHB or CHB-related com-
pensated or decompensated cirrhosis in medical records.
The hospital is the only one specializing in infectious dis-
eases locally, with the most number of outpatient visits
and admissions for viral hepatitis. Patients must be Han
Chinese aged 18 years or elder and have lived in Xi’an for
five years or more. CHB diagnosis and its classification
followed the standards in the Guideline of Prevention and
Treatment for Chronic Hepatitis B (China, 2005), which
are consistent with international consensus [4,7]. Decom-
pensated cirrhosis was defined as cirrhosis with a history
of ascites, variceal bleeding, or hepatic encephalopathy.
For discharged patients, if the diagnosis for CHB was up-
dated after discharge by a hospital specialist the relevant
medical record would be consulted. Patients were ex-
cluded if they had any other chronic diseases (e.g. hyper-
tension, heart disease, stroke, diabetes mellitus, chronic
lung disease, alcoholic or drug-induced liver disease, tu-
berculosis, psychological illness) or co-infections (hepatitis
C, hepatitis D or human immunodeficiency virus) identi-
fied by medical record review or the questionnaire survey;
or severe cognitive impairment identified by the inability
to understand informed consent.
Patients received an individual face-to-face interview
administered by one of trained interviewers in the hos-
pital or in their homes. They answered a structured
questionnaire that comprised of the Chinese (mainland)
Short Form 36 version 2 (SF-36v2), the Chinese (main-
land) Chronic Liver Disease Questionnaire (CLDQ) and
questions on socio-demographics, the history of CHB and
related treatment, and other chronic morbidities. Immedi-
ately after interview, a blood sample was collected for liver
function tests including alanine aminotransferase (ALT),
total bilirubin (TBIL) and albumin (ALB), which are the
most commonly used biomarkers reflecting hepatocellular
injury, liver excretory function and liver synthetic func-
tion, respectively [14].
A healthy control with matching sex, age (±5 years) and
occupation was selected for each patient in his/her resi-
dent sub-district by convenient sampling. The inclusion
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swered the same questionnaire administered like for pa-
tients, but without the questions of CLDQ. Liver function
tests were not provided for controls. The study protocol
was reviewed and approved by the Human Research
Ethics Committees of Xi’an Jiaotong University and the
Eighth Hospital of Xi’an, respectively. The written in-
formed consent was obtained from each recruited sub-
ject before the questionnaire survey.
Instruments and outcome measures
Chinese (mainland) SF-36v2
The SF-36v2 is a generic HRQoL measure which has
been widely used in general and specific populations
throughout the world [15]. It measures eight health do-
mains including physical functioning (PF), role-physical
(RP), bodily pain (BP), general health (GH), vitality (VT),
social functioning (SF), role-emotional (RE), and mental
health (MH). The eight domains are aggregated into two
summary measures: physical component summary (PCS)
and mental component summary (MCS). The standard
(4-week recall) Chinese (mainland) form was provided
by QualityMetric Incorporated, which has been validated
in mainland Chinese CHB patients [16]. We scored all
domains and summaries as norm-based scores which
have the same general population mean of 50 and stand-
ard deviation of 10. The scoring was performed by
Health Outcomes™ Scoring Software 2.0 (QualityMetric
Incorporated), and the general U.S. population norms
embedded in the software were used as references due
to the lack of general mainland Chinese population
norms. For all domains and summaries, higher scores in-
dicate better HRQoL and scores (on group-level) less
than 47 indicate being below the average range for the
U.S. general population [15].
SF-6D
Although the SF-36v2 was not originally designed for
preference measurement, its 11 items were combined to
form the SF-6D, a preference-based measure for deriving
a preference index scored from 0 (death) to 1 (full health)
[13,17]. The SF-6D scoring model for Hong Kong Chinese
population has been established and validated by McGhee
et al. [18]. We converted SF-36v2 data to SF-6D prefer-
ence values using this model.
Chinese (mainland) CLDQ
The CLDQ developed by Younossi et al. is a commonly
used specific HRQoL measure for liver diseases [19]. It
consists of 29 items measuring six health domains on
abdominal symptoms (AB), fatigue (FA), systemic symp-
toms (SY), activity (AC), emotional function (EM), and
worry (WO). Each item is rated on a 7-point Likert
scale. Domain scores are calculated by the summatedaverages of the respective item scores. An overall score
is calculated by the mean of all domain scores. Each do-
main and the overall score range from 1 to 7, with
higher scores indicating better HRQoL. The Chinese
(mainland) CLDQ was provided by the developers of the
original and it has been validated in mainland Chinese
CHB patients [20].
Data analysis
Patients were considered as a whole, and were also divided
into three groups with different stages of illness: CHB,
compensated cirrhosis, and decompensated cirrhosis. One-
way ANOVA or Pearson’s chi-square test was used to
compare differences in socio-demographic and clinical
characteristics among three patient groups. Paired-samples
t-test was used to compare differences in SF-36v2 and SF-
6D scores between patients and controls. Paired differences
of SF-36v2 and SF-6D scores were calculated, and they and
CLDQ scores were compared among three patient groups
using one-way ANOVA or Kruskal-Wallis test. If signifi-
cant differences were found, pairwise multiple comparisons
were conducted to further examine differences between
groups. Multi-variable linear stepwise regression analyses
were performed to identify factors associated with HRQoL
scores in patients. Independent variables in each regression
analysis were same, including stage of illness and all socio-
demographic and clinical characteristics shown in Table 1.
All data analyses were carried out in SPSS 13.0, with
P value less than 0.05 as statistical significant level.
Results
Accomplishment of survey and quality of data
A total of 934 discharged patients within the definite
period of time met the inclusion criteria and had no
diagnosis of any other chronic diseases or co-infections
in their medical records. Of them, 323 could not be con-
tacted due to the absence or change of their telephone
numbers and 25 had died. Among 586 contacted pa-
tients, 263 refused the interview (132 were busy; 38 were
not interested; 31 had health problems; and 62 did not
give any reasons), 69 were excluded because they clearly
reported their histories and current treatments of other
chronic diseases, and 254 finished the questionnaire. A
total of 206 outpatients fulfilling the inclusion and exclu-
sion criteria were approached, and they all answered the
questionnaire. Therefore, a total of 460 patients were en-
rolled in this study, including 323 with CHB, 54 with
compensated cirrhosis and 83 with decompensated cir-
rhosis. However, only 375 patients (311, 34 and 30 in the
corresponding patient groups above) provided blood
samples. Along with the enrollment of patients, 460
pair-matched healthy controls were recruited.
All 920 questionnaires were answered completely, with-
out any missing questions. For the SF-36v2, the quality of






cirrhosis (n = 54)
Decompensated
cirrhosis (n = 83)
Age (years, mean ± SD)† 35.8 ± 12.8 31.5 ± 10.9 43.0 ± 10.3 47.4 ± 11.7
Sex (%)
Male 66.3 65.6 72.2 65.1
Female 33.7 34.4 27.8 34.9
Occupation (%)†
Peasants 33.3 22.6 48.1 65.1
Service and commercial workers 17.0 18.9 14.8 10.9
Enterprise and institution staff 13.3 14.9 14.8 6.0
Unemployees 13.2 16.1 5.6 7.2
Self-employed persons 8.0 9.3 7.4 3.6
Students 7.4 10.5 0.0 0.0
Others 7.8 7.7 9.3 7.2
Education attainment (%)†
No schooling and primary 13.7 9.6 20.4 25.3
Secondary 67.6 67.2 66.7 69.9
Tertiary 18.7 23.2 12.9 4.8
Marital status (%)†
Married 71.3 61.9 96.3 91.6
Other marital status 28.7 38.1 3.7 8.4
Annual per capita household income (Chinese $, %)†
<5000 51.3 45.5 61.1 67.5
5000–9999 24.1 27.3 18.5 15.7
≥10000 24.6 27.2 20.4 16.8
Duration of illness (years, mean ± SD) 6.1 ± 6.9 6.0 ± 6.5 6.4 ± 6.7 6.3 ± 8.2
Currently taken anti-viraltreatment (%)†
No 61.1 67.2 50.0 44.6
Yes 38.9 32.8 50.0 55.4
Liver function tests*
ALT (U/L, mean ± SD) 61.9 ± 95.0 62.1 ± 100.2 52.4 ± 40.9 70.4 ± 83.1
TBIL (umol/L, mean ± SD)† 19.7 ± 20.3 16.5 ± 7.3 24.8 ± 13.7 46.7 ± 60.4
ALB (g/L, mean ± SD)† 44.1 ± 4.8 45.0 ± 4.0 42.7 ± 4.7 36.0 ± 4.6
ALT, alanine aminotransferase; TBIL, total bilirubin; ALB, albumin.
*Only including 375 patients receiving liver function tests: 311, 34 and 30 in chronic hepatitis B, compensated cirrhosis and decompensated cirrhosis groups, respectively.
†Significant difference among three patient groups (P < 0.05).
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seven quantitative checks (completeness of data, re-
sponses outside of range, consistent responses, percentage
of estimable scale scores, item internal consistency, item
discriminant validity, and scale reliability) were within ac-
ceptable ranges suggested by QualityMetric [15].
Patients’ characteristics
Table 1 showed socio-demographic and clinical character-
istics of patients overall and by groups. There were signifi-
cant differences in these characteristics among three
patient groups except sex, duration of illness and ALTlevel. The duration of illness was defined as the self-
reported time from the first diagnosis for CHB by a regis-
tered medical practitioner to the day of the interview.
The socio-demographic characteristics besides those
for matching, i.e. education attainment, marital status
and annual per capita household income, were also com-
parable between patients and controls overall and by
groups (P > 0.05).
SF-36v2 scores
Figure 1 demonstrated the SF-36v2 profile of scores for
all patients compared with controls. Controls had mean























































Figure 1 Mean norm-based scores of SF-36v2 health domains and component summary measures in all 460 chronic hepatitis B patients
compared with pair-matched healthy controls. PCS, physical component summary; MCS, mental component summary; PF, physical functioning;
RP, role-physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role-emotional; MH, mental health. *All differences
are statistically significant (P < 0.001).
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mains, but patients less than 47 on MCS and RP, GH, SF,
RE and MH. Patients scored significantly lower than con-
trols on all summaries and domains (P < 0.001), with differ-
ences of means (i.e. average paired differences) from 3.2 to
10.1 which were all greater than the suggested minimally
important difference (MID) values by QualityMetric, com-
monly 2 to 3 for group-level comparisons [15].
Figure 2 further showed that three patient groups
scored significantly lower than respective controls on all
summaries and domains. All average paired differences
but 1.9 on PF of CHB group were greater than the sug-
gested MID values. Comparing these average paired dif-
ferences among three patient groups, CHB group was
the lowest on all summaries and domains except BP,
significantly different from any (or one) of two other
groups on PCS and half of the domains. However, no
any significant differences were found between compen-
sated and decompensated cirrhosis groups. With disease
progression from CHB to compensated cirrhosis and to
decompensated cirrhosis, the average paired differences
on PCS and on PF and RP, both have the greatest phys-
ical factor content among the eight domains, gradually
increased. This trend did not appear on MCS and any
domains which contribute more to the scoring of MCS
(i.e. MH, RE, ST and VT).
SF-6D values
As shown in Table 2, patients overall and by groups had
significantly lower SF-6D values than respective controls(P < 0.001), decreasing by 12.26% (0.095/0.775) overall
and by 9.78% (0.075/0.767), 19.52% (0.154/0.789) and
16.62% (0.132/0.794) in CHB, compensated cirrhosis and
decompensated cirrhosis groups, respectively. Average
paired differences were significantly different between
CHB group and any of two other groups (P < 0.01), but
not between compensated and decompensated cirrhosis
groups.
CLDQ scores
CLDQ scores of patients overall and by groups were
shown in Table 3. CHB group among three patient groups
scored the highest on overall score and all domains except
WO, significantly different from any (or one) of two other
groups on overall score and half of the domains. However,
there were no any significant differences between com-
pensated and decompensated cirrhosis groups. Like the
results of SF-36v2, increasing HRQoL impairment with
disease progression appeared on physical health indicated
by decreasing mean scores on AB, SY and AC, but not on
mental health (i.e. EM and WO).
Factors associated with HRQoL in CHB patients
The factors selected by the stepwise regression analyses
on different summary or overall HRQoL scores were
showed in Table 4. Stage of illness reflecting disease pro-
gression was associated only with SF-36v2 PCS score,
with a negative relationship. Impaired liver function, in-
dicated by higher TBIL levels, was associated with lower
SF-36v2 PCS and SF-6D scores. Longer duration of
PCS† MCS PF† RP† BP GH VT† SF RE† MH
5.84.1 1.9 4.1 4.2 9.2 5.1 7.1 3.5 5.5
8.1‡ 9.1 5.4‡ 11.0‡ 5.4 12.8 10.3‡ 10.4 8.8‡ 6.9





























Figure 2 Mean norm-based scores of SF-36v2 health domains and component summary measures by patient groups, compared with
respective pair-matched healthy controls. CHB, chronic hepatitis B; CC, compensated cirrhosis; DCC, decompensated cirrhosis; PCS, physical
component summary; MCS, mental component summary; PF, physical functioning; RP, role-physical; BP, bodily pain; GH, general health; VT, vitality;
SF, social functioning; RE, role-emotional; MH, mental health. *All differences are statistically significant (P < 0.05). †Significant difference among
three patient groups (P < 0.05). ‡Significantly different compared with CHB group (P < 0.05).
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and CLDQ overall scores. Currently taken anti-viral treat-
ment negatively correlated with SF-36v2 MCS, SF-6D and
CLDQ overall scores. The regression analyses using each
domain score of SF-36v2 or CLDQ as dependent variable
further found that currently taken anti-viral treatment had
a significantly negative correlation with almost all the do-
mains which contribute more to the evaluation of mental
health, but only a few of the domains which contribute
more to the evaluation of physical health.
A few socio-demographic factors also influenced
HRQoL scores. Education attainment was positively re-
lated to SF-36v2 PCS and MCS and SF-6D scores. In-
creasing age had a negative effect on CLDQ overall
score and SF-6D value. Annual per capita household in-
come was associated only with CLDQ overall score, with
a positive relationship.
Discussion
Although HRQoL of CHB patients has been evaluated in
several counties and regions [7-11], the current study
from mainland China where has a high HBV prevalenceTable 2 SF-6D values (mean ± SD) of chronic hepatitis B patie
Overall (n = 460) Chronic hepatitis B (n = 323) C
Controls 0.775 ± 0.128 0.767 ± 0.128 0
Patients 0.680 ± 0.122 0.692 ± 0.120 0
Differences*† 0.095 ± 0.182 0.075 ± 0.181 0
*All differences are statistically significant (P < 0.001).
†Significant difference among three patient groups (P = 0.001).
‡Significantly different compared with chronic hepatitis B group (P < 0.01).and the largest CHB population in the world may provide
important evidence for expanding the knowledge about
the impact of CHB on health of people. The pair-matched
healthy controls and the exclusion of patients with any
other chronic diseases are distinguishing features of the
current study, which can better control the influence of
confounding factors and accurately characterize the im-
pact of CHB. A generic instrument provides a global as-
sessment and allows for comparisons with other health
conditions, while a disease-specific instrument addresses
some important HRQoL domains specifically associated
with this disease. Both used together may also verify each
other’s findings.
Our study found that CHB patients had significantly
lower SF-36v2 scores than healthy controls on all sum-
maries and domains regardless of whether with or with-
out cirrhosis. These HRQoL impairments were clinically
significant according to the suggested MID values [15].
The similar results were reported by the study from
Hong Kong in which the Chinese (Hong Kong) SF-36v2
was used and local general population norms were taken
as controls [8]. In this previous study, however, MCSnts compared with pair-matched healthy controls
ompensated cirrhosis (n = 54) Decompensated cirrhosis (n = 83)
.789 ± 0.122 0.794 ± 0.130
.635 ± 0.106 0.662 ± 0.131
.154 ± 0.153‡ 0.132 ± 0.192‡
Table 3 CLDQ scores (mean ± SD) of chronic hepatitis B patients
Overall (n = 460) Chronic hepatitis B (n = 323) Compensated cirrhosis (n = 54) Decompensated cirrhosis (n = 83)
AB* 5.5 ± 1.1 5.6 ± 1.1 5.4 ± 1.0 5.1 ± 1.2†
FA 4.8 ± 1.1 4.8 ± 1.1 4.6 ± 1.1 4.6 ± 1.2
SY* 5.4 ± 0.9 5.5 ± 0.8 5.3 ± 0.8† 5.0 ± 0.9†
AC* 5.5 ± 1.1 5.7 ± 1.0 5.0 ± 1.2† 4.8 ± 1.1†
EM 4.8 ± 1.1 4.9 ± 1.1 4.7 ± 0.9 4.9 ± 1.1
WO 5.1 ± 1.2 5.0 ± 1.2 4.9 ± 1.1 5.2 ± 1.0
Overall* 5.2 ± 0.8 5.3 ± 0.8 5.0 ± 0.7† 4.9 ± 0.8†
AB, abdominal symptoms; FA, fatigue; SY, systemic symptoms; AC, activity; EM, emotional function; WO, worry.
*Significant difference among three patient groups (P < 0.05).
†Significantly different compared with chronic hepatitis B group (P < 0.05).
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local general population. The SF-36v2 MCS measures
global mental health: a low score indicates frequent
psychological distress and social and role disability due
to emotional problems [15]. It is inferred that com-
pared with the CHB patients living in Hong Kong
where has the similar HBV prevalence but markedly
higher socioeconomic status and healthcare level, our
CHB patients suffer more serious emotional problems
and so more frequent psychological distress and more
substantial social and role disability. Although the pre-
vious studies from other countries and regions reported
impaired HRQoL in CHB patients with or without cir-
rhosis [7-11], almost all showed the impairment on
some but not all dimensions [7-9,11].Table 4 Multi-variable linear stepwise regression on HRQoL s
Dependent variable Independent variable entered in the model Uns
SF-36v2 (PCS) Stage of illness −2.5
Total bilirubin −0.0
Education attainment 1.90
Duration of illness −0.1
SF-36v2 (MCS) Currently taken anti-viral treatment −3.8
Education attainment 2.18
Duration of illness −0.1




CLDQ (Overall) Age −0.0
Annual per capita household income 0.13
Duration of illness −0.0
Currently taken anti-viral treatment −0.2
*Only 375 patients with liver function tests are included in the analyses. PCS, physic
variables include stage of illness (chronic hepatitis B = 1, compensated cirrhosis = 2,
variable); education attainment (no schooling and primary = 1, secondary = 2, tertia
household income (<5000 = 1, 5000–9999 = 2, ≥10000 = 3); currently taken anti-vira
illness, alanine aminotransferase, total bilirubin, and albumin). A variable is entered
removed if greater than 0.1.Our results from both the SF-36v2 and the CLDQ
showed that HRQoL of CHB patients significantly deterio-
rated with development of cirrhosis, and that the impair-
ment on physical components had a gradually increasing
trend with disease progression. These findings were con-
sistent with those in the Hong Kong and the Singapore
studies [7,8]. Our study did not find any significant differ-
ences in HRQoL impairment between compensated and
decompensated cirrhosis patients. Small sample sizes in
both groups might be an explication. More possibly, how-
ever, it suggested similar impairment between the two
types of patients. The serious complications of ascites,
variceal bleeding or hepatic encephalopathy may be re-
lieved after successful treatment, and the patients classi-
fied as with decompensated cirrhosis according to theircores in chronic hepatitis B patients*
tandardized coefficient (95% CI) Standardized coefficient P value
48 (−3.795, −1.302) −0.212 0.000
60 (−0.096, −0.024) −0.171 0.001
1 (0.687, 3.116) 0.149 0.002
10 (−0.213, −0.008) −0.102 0.035
95 (−6.147, −1.644) −0.174 0.001
0 (0.247, 4.112) 0.113 0.027
70 (−0.335, −0.006) −0.104 0.043
41 (−0.066, −0.016) −0.164 0.001
5 (0.003, 0.048) 0.117 0.029
01 (−0.001, 0.000) −0.107 0.036
01 (−0.002, 0.000) −0.095 0.076
13 (−0.020, −0.006) −0.182 0.000
8 (0.038, 0.238) 0.138 0.007
17 (−0.030, −0.003) −0.131 0.013
03 (−0.375, −0.030) −0.116 0.022
al component summary; MCS, mental component summary. Independent
decompensated cirrhosis = 3); sex (male = 1, female = 2); occupation (dummy
ry = 3); marital status (married = 1, other marital status = 2); annual per capita
l treatment (no = 1, yes = 2); and other quantitative variables (age, duration of
into the model if the significance level of its F value is less than 0.05 and is
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poorer physical health status than those with compensated
cirrhosis in their daily life. In addition, adaptation and
positive coping behaviors may lead to a positive response
shift in patients’ psychological perceptions [8].
As expected, the SF-6D values also indicated signifi-
cant health impairment in CHB patients regardless of
whether with or without cirrhosis. The Hong Kong study
reported the SF-6D values of 0.755, 0.745, 0.720 and 0.701
in CHB patients with uncomplicated disease, impaired
liver function, hepatocellular carcinoma and cirrhosis, re-
spectively, and 0.787 in local general population [8]. Our
healthy controls had the same level of preference for their
health status as Hong Kong general population, but our
CHB patients lower than the CHB patients living in Hong
Kong. In the only study touching upon mainland Chinese
preferences for CHB-related health states [12], with the
standard gamble method the preference values elicited
from uninfected individuals for CHB and compensated
cirrhosis were between 0.7 and 0.8, similar to the Hong
Kong’s results but higher than ours. However, the prefer-
ence values elicited from uninfected individuals for de-
compensated cirrhosis and elicited from CHB patients for
all CHB-related states were from 2.5 to 0.6, obviously
lower than the Hong Kong’s and our results. The dispar-
ities may be caused by differences in participants and pref-
erence evaluation methods [12,13]. In addition, another
difference should be noted. In the Hong Kong and our
studies, the patients selected from outpatients or past dis-
charged patients reported their perceptions based on their
own health status in daily life, when some serious or typ-
ical symptoms may be relieved. In the study with the
standard gamble method [12], however, the respondents
reported their perceptions based on the pre-set health
state-specific indications. For example, decompensated
cirrhosis is indicated as “sometimes I vomit blood and
have to go to the hospital for a blood transfusion and to
have a tube placed in my stomach through my nose”. This
might induce respondents to give their response to typical
symptoms presented only at the onset stage usually with
needs of in-hospital treatment. CHB is a chronic disease
and the vast majority patients will live with it till death [4].
The onset of typical symptoms is only an episode in the
long disease history, though it may repeat. Therefore, the
Hong Kong’s and our results should be more suitable for
use in the cost-effectiveness evaluation of interventions
with long-term or lifelong impacts. There was no signifi-
cant difference in SF-6D value impairment between
compensated and decompensated cirrhosis patients in
our study. Whether it means the difference of preference
between the two states is negligible in relevant cost-
effectiveness evaluations, further studies are needed.
The stepwise regression analyses further confirmed the
association of HRQoL and stages of CHB: more advancedstages with lower physical health. TBIL level may be
considered as an important biomarker associated with
physical health of CHB patients. The Hong Kong study
also reported the association of higher TBIL levels with
lower SF-36v2 PCS scores [8]. Currently taken anti-
viral treatment was found having a negative relationship
with HRQoL of CHB patients, especially on mental di-
mensions. This could be due to side effects of treatment
or the selection of the patients who were more ill or anx-
ious for treatment [8]. Previous studies on patients with
hepatitis C also found that anti-viral treatment reduced
HRQoL initially [21], but an improvement was observed
after successful treatment [22]. Education attainment and
annual per capita household income were positively re-
lated to HRQoL of CHB patients. The two factors were
rarely addressed in the previous studies. This finding is
particularly significant in mainland China, where most
CHB cases occur in rural areas with low socioeconomic
status and poor education and the treatment places a
heavy economic burden on patients and their families
[23], which may hinder patients taking regular treatment
and increase patients’ worry [24]. It suggests that reducing
treatment cost burden and providing health education
might play certain roles in improving HRQoL of CHB pa-
tients in mainland China.
There were two major limitations in our study. The
study was implemented only in an area that limited the
generalizability of the results for whole mainland China.
The small sample sizes in compensated and decompen-
sated cirrhosis patients limited the power of the related
results for drawing more exact conclusions.
Conclusions
Mainland Chinese CHB patients suffered significant HRQoL
impairment on all dimensions, and the impairment
reached a high level on mental health at initial stage of
illness and increased gradually on physical health with
disease progression. CHB patients with compensated
and with decompensated cirrhosis had similar total
HRQoL impairment in their daily life. The SF-6D pref-
erence values obtained can be used in relevant cost-
effectiveness evaluations. In order to improve HRQoL of
CHB patients, attention should be paid to the reduction of
patients’ treatment cost burden and the provision of early
health education accompanied with proper treatments.
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